Rapid restoration of coronary blood flow through primary percutaneous intervention (PPCI) remains the gold standard management of acute ST-elevation myocardial infarction (STEMI). As the availability of primary interventional facilities has improved, door to balloon times have fallen and this has been rewarded with concomitant reductions in mortality and morbidity. 1 The question remains, however, even with PPCI and the associated evolution of optimized medical therapy, of whether we doing absolutely everything to preserve the jeopardized myocardium. In the face of improved clinical outcomes, it may be difficult to envisage where any further improvement might come from. Rapid recanalization/reperfusion of an occluded epicardial artery is a paradoxical phenomenon due to its association with reperfusion-induced injury. Reperfusion is indispensable for reviving the myocardium at risk of necrosis, but the reintroduction of oxygen leads to the generation of damaging reactive oxygen species, whereas re-energization of the processes necessary to maintain cellular ion homeostasis leads to rapid intracellular alkalization, which, combined with intracellular and mitochondrial calcium overload, represent the 'perfect storm' for initiation of cell death signalling cascades. 2 The extension of the myocardial infarct by reperfusion is not necessarily inevitable. An intervention known as ischaemic conditioning was recognized in animal models as early as 1986 3 and is capable of reducing infarct size in these models by up to 50%. 4 Ischaemic conditioning, whereby brief, repetitive, non-injurious ischaemia, before (pre-conditioning), during (per-conditioning), or immediately following (post-conditioning) the onset of the injurious ischaemic insult, has been shown to be effective in small clinical trials, typically using cardiac enzyme release as a primary endpoint, in the setting of both cardiac surgery and, more recently, STEMI.
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Classical conditioning, whereby the conditioning protocol needs to be directly applied to the heart, may be perceived to add to the heart's ischaemic burden through accruing intermittent occlusion of coronary flow with the total ischaemic time of the injurious insult; is invasive and therefore not without risk of distal atheromatous embolization into the microvasculature; and, as in the case of pre-conditioning, it needs to be instituted prior to an acute myocardial infarction, making it almost impossible to apply in the context of an acute coronary syndrome (ACS). Therefore, unsurprisingly, widespread adoption of classical conditioning has been slow, and it is likely to remain an experimental procedure. The prospective game-changer with regard to clinical application has been the discovery that it is not necessary to condition directly the area of heart being subjected to injurious ischaemia: it is possible to induce protection in the area remotely-be that through transient, intermittent occlusion of a non-culprit artery, 6 or through transient, intermittent ischaemia of a distant organ or tissue bed. 7 Indeed, it has been found that the simple application of a blood pressure cuff to the upper arm and inflating this to 200 mmHg for 5 min, and repeating this three or four times interspersed by 5 min reperfusion periods, is sufficient to trigger significant protection in a variety of organs, not just the heart 8 ( Figure 1 ). Bøtker and colleagues have previously shown that remote ischaemic conditioning can attenuate infarct size following PPCI using gated single photon emission computed tomography (SPECT) to determine the area at risk and extent of infarction, demonstrating a significant increase in mean myocardial salvage from 57% to 69% by remote ischaemic conditioning over controls (P ¼ 0.0333) in the 251 patients who consequently proceeded to PPCI. 9 These data were in line with encouraging results from a number of proof-of-concept trials looking at classical direct post-conditioning of the myocardium following successful PPCI. 5 The critical missing piece of the jigsaw necessary to implement ischaemic conditioning in routine clinical practice is convincing clinical outcome data. The study of Sloth et al. is an important stepping stone to achieving this goal, presenting a follow-up (median 3.8 years) of the 333 patient cohort of the original trial of 2010. 9 Data were accrued for the primary endpoint, major adverse cardiovascular and cerebrovascular events (MACCEs): a composite of all-cause mortality, myocardial infarction, readmission for heart failure, and ischaemic stroke/transient ischaemic attack. 10 In line with the earlier myocardial salvage findings, the authors report significantly fewer MACCEs in the remote ischaemic-conditioned group compared with controls [13.5% vs. 25.6%, respectively, giving a hazard ratio (HR) of 0.49, 95% confidence interval (CI) 0.27-0.89, P ¼ 0.018]. The difference in MACCE rate was driven by a difference in all-cause mortality (4.0% vs. 12.0%, HR 0.32, 95% CI 0.12-0.88, P ¼ 0.027), although there was a generally positive trend for benefit in cardiovascular endpoints in the treatment arm.
The predominant difference in all-cause mortality was the lower rate of cancer deaths in the remote ischaemic conditioning group (half of that reported in the placebo group). The authors are rightly cautious in their interpretation of this finding, which is likely to reflect the relatively small patient numbers; the original study was not powered to assess clinical outcomes. Interestingly, however, there is an overlap in the risk factor profile for patients with cardiovascular disease and visceral cancers, 11 and it is not known whether there is a lower mitogenic threshold to ionizing radiation in at-risk cardiovascular patients. However, while PPCI represents a significant exposure to ionizing radiation (estimated to be 136 + 98 Gy cm 2 ), particularly for mediastinal structures, 12 the life-attributable risk of the radiation received as a consequence of PPCI is not estimated to be high. 12 Intriguingly,although data from animal models show that remote ischaemic conditioning can attenuate the acute cellular injury associated with ionizing radiation, 13 there is no evidence to suggest that remote ischaemic conditioning is an explanation of the reduction of cancer deaths in this study. Conflict of interest: none declared. Figure 1 The model of ubiquitous protection by remote ischaemic conditioning. Inflation of a blood pressure cuff to induce transient limb ischaemia leads to initiation of both a humeral pathway (red) and a neural pathway (blue). 15 This in turn leads to protection, in near ubiquitous fashion, of all visceral organs. 
